Cost-Minimization Analysis (CMA) of Canagliflozin Compared to Glimepiride and Sitagliptin as Dual Therapy in Combination with Metformin
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.2111
https://www.valueinhealthjournal.com/article/S1098-3015(15)04187-X/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
1527
First Page :
A610
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04187-X&doi=10.1016/j.jval.2015.09.2111